Mineralocorticoid receptor antagonists: a dubious past and advanced future

Cover Page

Cite item

Full Text

Abstract

The review article shows the literature data concerning the usage of mineralocorticoid receptor antagonists of the Russian market, - spironolactone and eplerenone in different groups of patient, including primary hyperaldosteronism, arterial hypertension, heart failure, myocardial infarction, chronic kidney disease. The special attention is paid to the questions of tolerance of the drug and safety. We made an attempt to use differential approaches in the choice of spironolactone and eplerenone application in different subgroups of patients.

About the authors

D. A Napalkov

I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation

Email: dminap@mail.ru
д-р мед. наук, проф. каф. факультетской терапии №1 ГБОУ ВПО Первый МГМУ им. И.М.Сеченова 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2

References

  1. Tamargo H, Solini A, Ruilope L.M. Comparison of agents that affect aldosterone action. Semin Nephrol 2014; 34: 285-306.
  2. Messaoudi S, Jaisser F. Aldosterone and the mineralocorticoid receptor. Eur Heart J Suppl 2011; 13: B4-В9.
  3. Brown N.J. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol 2013; 9: 459-69.
  4. Williams J.S, Williams G.H. 50th anniversary of aldosterone. J Clin Endocrinol Metab 2003; 88: 2364-72.
  5. Messaoudi S, Azibani F, Delcayre C et al. Aldosterone, mineralocorticoid receptor, and heart failure. Moll Cell Endocrinol 2012; 350: 266-72.
  6. Bledsoe R.K, Madauss K.P, Holt J.A et al. A ligand - mediated hydrogen bond network required for the activation of the mineralocorticoid receptors. J Biol Chem 2005; 280 (31): 283-93.
  7. Fagart J, Huyet J, Pinon G.M et al. Crystal structure of a mutant mineralocorticoid receptor responsible for hypertension. Nat Struct Mol Biol 2005; 12: 554-5.
  8. Hultman M.L, Krasnoperova N.V, Li S et al. The ligand - dependent interaction of mineralocorticoid receptor with coactivator and corepressor peptides suggests multiple activation mechanisms. Mol Endocrinol 2005; 19: 1460-73.
  9. Sica D.A. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev 2005; 10: 23-9.
  10. Garthwaite S.M, Mc Mahon E.G. The evolution of aldosterone antagonists. Moll Cell Endocrinol 2004; 217: 27-31.
  11. Rossi G.P. A comprehensive review of the clinical aspects of primary aldosteronism. Nat Rev Endocrinol 2011; 7: 485-95.
  12. Karagiannis A, Tziomalos K, Papageorgiou A et al. Spironolactone vs. eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin Pharmacother 2008; 9: 509-15.
  13. Partharasarathy H.K, Menard J, White W.B et al. A double - blind randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens 2011; 29: 980-90.
  14. Newton-Cheh C, Guo S.Y, Gona P et al. Clinical and genetic correlates of aldosterone of aldosterone - to - renin ratio and relations to blood pressure in a community sample. Hypertension 2007; 49: 846-56.
  15. Meneton P, Galan P, Bertrais S et al. High plasma aldosterone and low renin predict blood pressure increase and hypertension in middle - aged Caucasian populations. J Hum Hypertens 2008; 22: 550-8.
  16. Nishizaka M.K, Zaman M.A, Calhoun D.A. Efficacy of low - dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003; 16: 925-30.
  17. Chapman N, Dobson J, Wilson S et al. Anglo-Scandinavian Outcomes Trial Investigators. Effects of spironolacton on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49: 839-45.
  18. Weinberger M.H, White W.B, Ruilope L.M et al. Effects of eplerenone versus losartan in patients with low - renin hypertension. Am Heart J 2005; 150: 426-33.
  19. Pitt B, Reichek N, Willenbrock R et al. Effects of eplerenone, enalapril and eplerenone/enalapril in patients with essential hypertension and left ventricle hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003; 108: 1831-8.
  20. Calhoun D.A, White W.B. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens 2008; 2: 462-8.
  21. Zannad F, Gattis Stough W, Rossignol P et al. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence in clinical practice. Eur Heart J 2012; 33: 2782-95.
  22. Swedberg K, Eneroth P, Kjekshus J et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS trial study Group. Circulation 1990; 82: 1730-6.
  23. Yancy C.W, Jessup M, Bozkurt B et al. 2013 ACCF/AHA Guideline for the management of heart failure. J Am Coll Card 2013; 62 (16): e147-e239.
  24. Milliez P, Deangelis N, Rucker-Martin C et al. Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur Heart J 2005; 26: 2193-9.
  25. Beygui F, Labbe J.P, Cayla G et al. Early mineralocorticoid receptor blockade in primary percutaneous coronary intervention for ST-elevation myocardial infarction is associated with a reduction of life - threating ventricular arrhythmia. Int J Cadiol 2013; 167: 73-9.
  26. Swedberg K, Zannad F, Mc Murray J.J et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Elerenone in Mild Patients Hospitalization and Survival Study in Heart Failure) study. J Am Coll Cardiol 2012; 59: 1598-603.
  27. Mc Manus F, Mc Innes G.T, Connell J.M. Drug insight: eplerenone, a mineralocorticoid receptor antagonist. Nat Clin Pract Endocrinol Metab 2008; 4: 44-52.
  28. Epstein M, Williams G.H, Weinberger M et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006; 1: 940-51.
  29. Navaneethan S.D, Nigwekar S.U, Sehgal A.R et al. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta - analysis. Clin J Am Kidney Dis 2009; 4: 542-51.
  30. Gulmez S.E, Lassen A.T, Aalykke C et al. Spironolactone use and the risk of upper gastrointestinal bleeding: a population - based case - control study. Br J Clin Pharmacol 2008; 66: 294-99.
  31. Jeunemaitre X, Chatellier G, Kreft-Jais C et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987; 60: 820-5.
  32. Pitt B, Zannad F, Remme W.J et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-17.
  33. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-21.
  34. Zannad F, Mc Murray J.J, Krum H et al. for the EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21.
  35. Pitt B, Bakris G, Ruilope L.M et al. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 2008; 118: 1643-50.
  36. Ezekowitz J.A, Mc Alister F.A. Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. Eur Heart J 2009; 30: 469-77.
  37. Eschalier R, Mc Murray J.J, Swedberg K et al. EMPHASIS-HF Investigators. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalizations And Survival Study in Heart Failure). J Am Coll Cardiol 2013; 62: 1585-93.

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies